Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults

The tyrosine receptor kinase (TRK) inhibitors larotrectinib and entrectinib were recently approved in Canada for the treatment of solid tumours harbouring neurotrophic tyrosine receptor kinase (<i>NTRK)</i> gene fusions. These <i>NTRK</i> gene fusions are oncogenic drivers found in most tumour types...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	D. Gwyn Bebb, Shantanu Banerji, Normand Blais, Patrice Desmeules, Sharlene Gill, Andrea Grin, Harriet Feilotter, Aaron R. Hansen, Martin Hyrcza, Monika Krzyzanowska, Barbara Melosky, Jonathan Noujaim, Bibiana Purgina, Dean Ruether, Christine E. Simmons, Denis Soulieres, Emina Emilia Torlakovic, Ming-Sound Tsao
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	MDPI AG 2021-01-01
Σειρά:	Current Oncology
Θέματα:	NTRK larotrectinib entrectinib targeted therapy molecular testing oncogenic drivers
Διαθέσιμο Online:	https://www.mdpi.com/1718-7729/28/1/53
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!